Table 2.

Candidate drugs for treatment of SCA17

Drugs	Ingredients	Targeted molecules	Pre-clinical studies	References
Trehalose	Disaccharide	NM	Reduced aggregation and ameliorated behavioral performances in SCA17 transgenic mice	[55]
EGb 761	Ginkgo biloba extract	NM	Reduced aggregation in the TBP/79Q cells model; Ameliorated motor function in SCA17 transgenic mice	[56]
G-CSF	Glycoprotein	Hsp70 Beclin-1 LC3-II	Improved motor coordination; Reduced cell loss and aggregation in SCA17 transgenic mice	[46]
Piperine	Alkaloid	MANF	Reduced ER stress in TBP/105Q cell model; Improved Purkinje cell survival and behavioral performances in SCA17 knock-in mice	[52]
NC009-1	Indole compound	HSPB1	Promoted neurite outgrowth in SCA17 cell model; Reduced aggregation and ameliorated behavioral deficits in SCA17 transgenic mice	[45]
SG-Tang	Formulated Chinese medicine	NFYA PGC-1a NRF2	Reduced aggregation and promoted neurite outgrowth in SCA17 cell model; Ameliorated behavioral deficits and reduced aggregation in SCA17 transgenic mice	[47]

NM not mentioned